Roche Tecentriq and Avastin first-line treatment is significant

recently, the evaluation of Roche anti-PD-L1 therapy Tecentriq (Tersanqi, generic name: atezolizumab, atzhu monoantigen) in combination with Avastin (Avetin, generic name: bevacizum) The results of the IMbrave150 Study (NCT03434379) of the first-line treatment of non-excisive hepatocellular carcinoma (HCC) III (NCT03434379) were published in the New England Journal of Medicine (NEJM), the world's top medical journal. The article was headlined: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. The data showed that the Tecentriq-Avastin combined drug treatment was significantly more effective than the standard care drug sorafenib.IMbrave150 is an open-label, multi-center, randomized Phase III study conducted in patients with non-excisive, localized late stage or metastasis HCC who had not previously received systematic treatment to investigate the efficacy and safety of Tecentriq's combined treatment with Avastin's standard care drug, the multi-kinase inhibitor sorafenib. In the study, patients were randomly assigned a 2:1 ratio to receive Tecentriq-Avastin combined therapy (n-336) or solaffinie therapy (n-165) until an unacceptable toxic reaction or loss of clinical benefit. The common primary endpoint of the study was the total lifetime (OS) and progress-free lifetime (PFS) determined by the independent assessment body based on version 1.1 (RECIST 1.1) of the solid tumor efficacy evaluation criteria.The results showed that the study reached a common primary endpoint: both the Tecentriq-Avastin combined treatment group OS and PFS showed improvements in statistical and clinical significance compared to the Solafini group.The data were: significantly longer total survival of the Tecentriq-Avastin combined treatment group (medium OS: NE vs 13.2 months) and a 42% reduction in risk of death compared to the Sorafinie group at the main analysis point (29 August 2019) (HR: 0.58, 95% CI: 0.42-0.79, p<0.001), 12-month survival rate increased (67.2% vs 54.6%). In addition, compared to the Sorafini group, the non-progression survival of the Tecentriq-Avastin combined treatment group was significantly extended (medium PFS: 6.8 months vs. 4.3 months), and the risk of disease progression or death was reduced by 41% (HR-0.59,95% CI:0.47-0.76, p<0.001).In this study, the safety of Tecentriq and Avastin drugs was consistent with the known safety of each drug, and no new safety signals were found. For level 3 or 4 adverse events, the incidence of Tecentriq-Avastin combined treatment group was 56.5%, the sorapinie group was 55.1%, and the Tecentriq-Avastin combined treatment group had 15.2% of patients with grade 3 or 4 hypertension;Liver cancer is a major cause of death among the world, especially in Asia, and is the most common type of liver cell carcinoma. Based on these results, IMbrave150 is the first Phase III cancer immunotherapy study to show improvements in OS and PFS in the most common liver cancer treatments. Tecentriq's combination with Avastin is also the first treatment to improve total survival in patients with non-removable hepatocellular carcinoma who have not previously received systematic treatment for more than a decade.Regulatoryly, the FDA is currently reviewing additional applications for the Tecentriq-Avastin portfolio through the Real-Time Oncology Review Pilot Program. Previously, the program had been awarded breakthrough drug eligibility by the FDA. In China, the scheme was accepted by China's State Drug Administration (NMPA) in January.Roche has developed an extensive development program for Tecentriq, including a number of ongoing and planned Phase III studies on multiple types of lung, genitourinary, skin, breast, gastrointestinal, gynaecological and head and neck cancers. This includes studies of Tecentriq taking drugs alone or treating them in untreated with other drugs.Tecentriq is a PD-(L)1 tumor immunotherapy designed to bind to a protein called PD-L1 expressed on tumor cells and tumor-immersed immune cells, blocking its interaction with PD-1 and B7.1 receptors. By inhibiting PD-1, Tecentriq can activate T-cells, which have the potential to be a basic combination therapy for cancer immunotherapy, targeted drugs, and chemotherapy for various cancers.Avastin is an angiogenesic inhibitor that targets the binding of angio endosthort growth factor (VEGF). VEGF plays an important role in angiogenesic and maintenance throughout the tumor life cycle. Avastin infects the tumor's blood supply by binding directly to VEGF, preventing it from interacting with the subjects on the blood vessel cells. The blood supply of the tumor is considered to be the key to the tumor's ability to grow and metastasis in the body.The combination of Tecentriq and Avastin has a strong scientific basis, and the Tecentriq-Avastin combination has the potential to strengthen the immune system against tumors. In addition to its established anti-angiogenesic effects, Avastin can further enhance Tecentriq's ability to restore the body's anti-cancer immunity by inhibiting VEGF-related immunosuppression, promoting T-cell tumor immersion, and initiating T-cell response to tumor antigens.In December 2018, the FDA approved Tecentriq-Avastin-Chemotherapy (Caprain and Yew alcohol) for first-line treatment of metastasis non-squamous non-small cell lung cancer (NSq NSCLC) adult patients without EGFR or ALC genomic tumor distortion. The approval was based on group B patient data from the IMpower150 study: In patients with intentional therapy wild type (ITT-WT), Tecentriq-Avastin-chemotherapy significantly extended the survival of patients (medium OS: 19.2 months vs 14.7 months, HR=0.78, p=0.016) compared to Avastin-chemotherapy. (Bio Valley Bioon .com)